US Dietary Supplement Regulatory Uniformity Act progresses, threatens state-level divergence

Washington D.C., United States — 01 May 2026

US Representative Nick Langworthy's introduction of H.R. 7366, the Dietary Supplement Regulatory Uniformity Act, signals a legislative push to standardise dietary supplement regulation across the United States. The bill seeks to impose federal preemption, preventing individual states from enacting regulatory measures that diverge from federal law, unless such state-specific rules address unique local issues without conflicting with established federal requirements. This move is supported by industry groups, including the Natural Products Association (NPA), which advocates for a singular, science-backed national standard.

Currently, the US supplement market is fragmented by state-level legislative initiatives. States such as California and New York have either proposed or implemented distinct regulations covering ingredient bans, age restrictions, and specific labelling mandates. This regulatory patchwork presents significant compliance complexities and cost escalations for supplement manufacturers and brand owners operating across state lines. The industry argues that a uniform federal standard would diminish the need for multiple product formulations and varied labelling, thereby reducing operational overheads and market entry barriers.

The bill is positioned as a solution to the economic burden imposed by disparate state laws. NPA highlighted that without federal preemption, manufacturers face increased costs due to the necessity of developing state-specific product lines, managing complex supply chains, and navigating potential legal challenges arising from regulatory inconsistencies. Harmonising these standards would streamline production processes, potentially lowering manufacturing costs and improving product availability nationwide.

Critics of the bill may raise concerns about potential erosion of states' rights to protect their consumers from perceived health risks not adequately addressed by federal oversight. However, proponents stress that the Act is designed to foster a more predictable and efficient regulatory environment, ensuring that federal agencies like the FDA remain the primary authority for supplement safety and efficacy, while allowing for state intervention only on genuinely local issues.

What this means for United States

Brand owners and manufacturers in the United States face a critical juncture; continued state-level divergence increases compliance costs, potentially necessitating 5-8 distinct product formulations yearly to satisfy varying state requirements. Passage of H.R. 7366 would enable significant economies of scale, reducing SKU complexity and related inventory costs by up to 20%. Procurement teams must monitor the bill's progress to inform strategic ingredient sourcing and reformulation decisions. Conversely, failure of the bill could empower states like New York and California to enact stricter ingredient bans, forcing localised reformulation or market withdrawal for specific products, impacting market share and revenue lines.

What to watch next

• Monitor H.R. 7366's progress through the US House Committee on Energy and Commerce, particularly any amendments or co-sponsors by Q3 2026.
• Observe key industry lobby efforts by organisations like the Natural Products Association (NPA) and the Council for Responsible Nutrition (CRN) in Washington D.C. as the legislative session progresses through 2026.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.